Hepcludex 2.0

After about 5 years of Hepcludex it´s time to give a follow up on
the experiences with the drug. In this episode we talk to the
inventor of bulvertide, S. Urban (project leader in our TRR179)
and a clinician expert (P. Lampertico from Milan).


We will refer to the following questions:


Which patients benefit from bulevirtide? What about HCC and
decomp. cirrhosis?


Do we need interferon for best efficacy? Are the supply chains of
interferon a problem?


What do we do with treatment failures? When is someone a
treatment failure?


What else is there beyond bulevirtide?


What are the prospects for bulevirtide/entry inhibition in HBV
monoinfection?